Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Sequential, Open-Label Study of the Pharmacokinetics and Safety of Intravenous Carbamazepine Relative to Oral Carbamazepine in Adult Patients With Epilepsy.

Next Previous
Trial Profile

A Sequential, Open-Label Study of the Pharmacokinetics and Safety of Intravenous Carbamazepine Relative to Oral Carbamazepine in Adult Patients With Epilepsy.

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 11 May 2017

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Carbamazepine (Primary) ; Carbamazepine
  • Indications Epilepsy; Generalised seizures; Partial epilepsies; Tonic-clonic epilepsy
  • Focus Adverse reactions; Pharmacokinetics
  • Sponsors Lundbeck A/S

    • Most Recent Events

    • 28 Apr 2017 Results assessing the the pharmacokinetics of Capitsol in carbamazepine(CBZ)-treated patients with epilepsy by renal function status, presented at the 69th Annual Meeting of the American Academy of Neurology.
    • 28 Apr 2017 Results presented at the 69th Annual Meeting of the American Academy of Neurology.
    • 28 Apr 2017 Results comparing pharmacokinetics of oral carbamazepine (CBZ) and intravenous CBZ in patients by renal function status, presented at the 69th Annual Meeting of the American Academy of Neurology
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top